JP2018525371A - アリール置換された二環式ヘテロアリール化合物 - Google Patents

アリール置換された二環式ヘテロアリール化合物 Download PDF

Info

Publication number
JP2018525371A
JP2018525371A JP2018504757A JP2018504757A JP2018525371A JP 2018525371 A JP2018525371 A JP 2018525371A JP 2018504757 A JP2018504757 A JP 2018504757A JP 2018504757 A JP2018504757 A JP 2018504757A JP 2018525371 A JP2018525371 A JP 2018525371A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkoxy
alkylene
fluoroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018504757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525371A5 (enExample
Inventor
シャオジュン・ジャン
シャオファン・ジェン
ルイーズ・エス・チュパック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018525371A publication Critical patent/JP2018525371A/ja
Publication of JP2018525371A5 publication Critical patent/JP2018525371A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018504757A 2015-07-30 2016-07-28 アリール置換された二環式ヘテロアリール化合物 Ceased JP2018525371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198706P 2015-07-30 2015-07-30
US62/198,706 2015-07-30
PCT/US2016/044388 WO2017019828A1 (en) 2015-07-30 2016-07-28 Aryl substituted bicyclic heteroaryl compounds

Publications (2)

Publication Number Publication Date
JP2018525371A true JP2018525371A (ja) 2018-09-06
JP2018525371A5 JP2018525371A5 (enExample) 2019-08-15

Family

ID=56609996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504757A Ceased JP2018525371A (ja) 2015-07-30 2016-07-28 アリール置換された二環式ヘテロアリール化合物

Country Status (6)

Country Link
US (1) US10517870B2 (enExample)
EP (1) EP3328839A1 (enExample)
JP (1) JP2018525371A (enExample)
KR (1) KR20180030913A (enExample)
CN (1) CN108137514A (enExample)
WO (1) WO2017019828A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805030T3 (es) 2016-07-14 2021-02-10 Bristol Myers Squibb Co Compuestos monocíclicos sustituidos con heteroarilo
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
EP3484878B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2018013770A1 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2019113312A1 (en) * 2017-12-08 2019-06-13 Innocrin Pharmaceuticals, Inc. Anticancer compound process
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN116041341B (zh) * 2022-11-24 2025-02-28 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503093A (ja) * 1990-11-26 1994-04-07 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換された縮合複素環式除草剤
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP2011520941A (ja) * 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
WO2011156610A2 (en) * 2010-06-09 2011-12-15 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
JP2012522741A (ja) * 2009-04-02 2012-09-27 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング キノキサリン誘導体並びに良性の及び悪性の腫瘍疾患の治療のためのその使用
EP2514749A1 (en) * 2009-12-15 2012-10-24 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
JP2013503824A (ja) * 2009-09-04 2013-02-04 バイエル・ファルマ・アクチェンゲゼルシャフト チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
TW279162B (enExample) 1991-09-26 1996-06-21 Mitsubishi Chem Corp
ATE246184T1 (de) 1996-11-06 2003-08-15 Darwin Discovery Ltd Chinoline und deren therapeutische verwendung
WO1999050254A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
ZA200600424B (en) * 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
ES2652440T3 (es) * 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
MX2007008587A (es) * 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
EP2129379B1 (en) * 2007-02-20 2019-04-10 Novartis AG Imidazoquinolines as dual lipid kinase and mtor inhibitors
EP2150255A4 (en) * 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
WO2009021083A1 (en) * 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
IN2012DN05113A (enExample) * 2007-09-17 2015-10-23 Abbott Lab
JP5762971B2 (ja) * 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
TWI428332B (zh) * 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
PT2501698T (pt) 2009-11-18 2018-07-23 Nat Res Council Canada Monómeros fluorados, oligómeros e polímeros para utilização em dispositivos eletrónicos orgânicos
WO2012071414A2 (en) * 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
PT2705029T (pt) * 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102532932B (zh) 2012-01-12 2014-01-08 复旦大学 一类含有吡嗪环的有机染料及其制备方法和应用
BR112014032346A2 (pt) * 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
JP2016509576A (ja) * 2012-12-20 2016-03-31 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性ジヒドロキノキザリノン類
WO2015004533A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503093A (ja) * 1990-11-26 1994-04-07 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換された縮合複素環式除草剤
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
JP2011520941A (ja) * 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP2012522741A (ja) * 2009-04-02 2012-09-27 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング キノキサリン誘導体並びに良性の及び悪性の腫瘍疾患の治療のためのその使用
JP2013503824A (ja) * 2009-09-04 2013-02-04 バイエル・ファルマ・アクチェンゲゼルシャフト チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2514749A1 (en) * 2009-12-15 2012-10-24 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011156610A2 (en) * 2010-06-09 2011-12-15 Gilead Sciences, Inc. Inhibitors of hepatitis c virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 2, JPN6020020048, 2009, pages 397 - 400, ISSN: 0004428937 *
TETRAHEDRON LETTERS, vol. 30, no. 8, JPN6020020049, 1989, pages 935 - 936, ISSN: 0004428938 *

Also Published As

Publication number Publication date
EP3328839A1 (en) 2018-06-06
US10517870B2 (en) 2019-12-31
KR20180030913A (ko) 2018-03-26
US20180214445A1 (en) 2018-08-02
WO2017019828A1 (en) 2017-02-02
CN108137514A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
JP2018525371A (ja) アリール置換された二環式ヘテロアリール化合物
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
JP7102388B2 (ja) 単環式ヘテロアリール置換化合物
CN109863145B (zh) 用于治疗和预防乙型肝炎病毒感染的新的四氢异喹啉和四氢二氮杂萘化合物
CN109689649B (zh) 经二环杂芳基取代的化合物
TWI654172B (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
TW202321263A (zh) 磺醯胺衍生物、其製備方法及其在醫藥上的應用
WO2020063792A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
TW202035412A (zh) 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
JP2024533551A (ja) ナフチルアミン構造を有する低分子化合物とその使用
CN109311865A (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
WO2024056005A1 (zh) 多并环类化合物及其用途
CN104725295A (zh) 芳杂环类衍生物及其在药物上的应用
JP2006522023A (ja) 虚血損傷治療のための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−３−キノリンカルボニトリル
CN116693447B (zh) 酮酰胺类衍生物及其制药用途
CN116969918A (zh) 氟取代的吡啶酮类衍生物及其药物组合物、制备方法和用途
EP4118080B1 (en) Bcl-2 family proteins modulating compounds for cancer treatment
CN115557898B (zh) 一种咪唑类化合物、其中间体及应用
TWI905781B (zh) 脯胺醯羥化酶抑制劑及其用途
CN117285516A (zh) 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用
WO2025021158A1 (zh) 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
CN119306762A (zh) 基于不稳定的氨基酸的新型癌症protac药物化合物的设计与应用
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210407

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210727